Previous Article | Next Article 
Journal of Clinical Microbiology, June 2000, p. 2232-2239, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Evaluation of Immunoglobulin M (IgM) and IgG Enzyme
Immunoassays in Serologic Diagnosis of West Nile Virus
Infection
G.
Tardei,1
S.
Ruta,2
V.
Chitu,1
C.
Rossi,3
T. F.
Tsai,4,* and
C.
Cernescu2
Institute of Virology1
and Carol Davila University of Medicine and
Pharmacy,2 Bucharest, Romania; U.S. Army
Medical Institute of Infectious Diseases, Fort Detrick, Frederick,
Maryland 21702-50113; and Division of
Vector Borne Infectious Diseases, Centers for Disease Control and
Prevention, Fort Collins, Colorado 805224
Received 1 February 2000/Accepted 22 March 2000
 |
ABSTRACT |
A unique urban encephalitis epidemic in Romania signaled the
emergence of neurological infection due to West Nile (WN) virus as a
novel public health threat in Eastern Europe and provided an
opportunity to evaluate patterns of immunoglobulin G (IgG) and IgM
reactivity in IgM capture and IgG enzyme-linked immunosorbent assays
(ELISAs). WN virus infection was diagnosed serologically in 236 of 290 patients from whom acute serum or cerebrospinal fluid (CSF) samples
were available. In 37% of serum samples and in 25% of CSF samples
collected in the first week of illness, anti-WN virus IgM antibody was
detected in the absence of virus-specific IgG. The switch to an IgG
antibody response occurred after 4 to 5 days of illness and earlier in
CSF than in serum. A specific humoral immune response was detected in
the CSF before the serum in some patients for whom paired CSF and serum
samples from the same day were available. IgM antibody in convalescent
serum samples persisted beyond 2 months after the onset of illness in
more than 50% of patients. ELISA optical density values and antibody
concentrations were well correlated for both IgM and IgG immunoassays.
Anti-WN virus IgM antibody in acute-phase samples did not cross-react significantly with flaviviruses in other antigenic groups.
 |
INTRODUCTION |
West Nile (WN) fever is a
mosquito-borne flaviviral infection transmitted among vertebrates and
various Culex mosquito vectors in Africa, the Middle East,
areas of Europe, and Asia; virus isolates have also been recovered from
Australia and recently from the United States (1, 3, 12, 16, 17,
20). Humans and horses may develop illness after infection, but
they do not contribute to further viral amplification (12,
20). Although the infection is considered to be transmitted
mainly in an endemic pattern, especially in Africa, sizeable epidemics,
numbering hundreds or thousands of cases, have occurred on that
continent and in Israel (12, 15, 16, 20, 32). Smaller
outbreaks of human and/or equine cases have been reported in India,
Egypt, Algeria, Morocco, central and southern Europe, the Camargue of
France, and in the United States (1, 3, 13, 19). Clinically,
WN fever is an acute self-limited febrile illness accompanied by
headache, polyarthropathy, rash, and lymphadenopathy (15,
18). Rarely, acute hepatitis or pancreatitis has been
reported, and cases in the elderly have sometimes been
complicated by central nervous system (CNS) infection (5, 6,
10, 11, 20, 21, 32; D. G. Tsereteli, R. A. Tsiklauri, and E. A. Ivanidze, Proc. 8th Int. Congr. Infect. Dis.,
abstr. 60.006, p. 206, 1998).
Between July and September 1996, a WN fever epidemic centered in the
capital city of Bucharest led to over 800 suspected cases in southern
Romania (26, 31). A serosurvey in Bucharest disclosed low
rates of WN virus antibodies, reflecting an immunologically naive
population in which a novel viral infection produced disease in
epidemic proportion (31). The severity of illness in the outbreak was unusual. Most patients were hospitalized with signs of CNS
infection, and the fatality rate in elderly people was 6%. WN virus
was confirmed as the etiology of the outbreak serologically and by the
isolation of WN virus from an acute-phase cerebrospinal fluid (CSF)
sample in one case (24, 31). The virus was also isolated
from a pool of Culex pipiens mosquitoes collected in Bucharest (26). Individual cases were confirmed
serologically using previously unevaluated immunoglobulin M (IgM)
antibody capture (MAC) and IgG direct enzyme-linked immunosorbent
assays (ELISAs). The purpose of the present study was to
characterize the peripheral and intrathecal antibody responses to
infection and to describe the performance of these immunoenzymatic assays.
 |
MATERIALS AND METHODS |
Patients and samples.
Study patients were admitted
to two infectious disease hospitals in Bucharest during an outbreak of
viral meningoencephalitis from late July through early October 1996. The clinical case definition used in the epidemic investigation was
acute aseptic meningitis, encephalitis, or meningoencephalitis of
suspected viral etiology, with a CSF pleocytosis. One or more serum
and/or CSF samples were received from 290 patients for laboratory
diagnosis, including some patients who did not meet all clinical
criteria of the case definition but who had other signs of an acute
infection during the epidemic period (Table
1). Each sample was aliquoted and stored
at
20°C for a maximum of 2 months and thawed just before being
tested. Computerized clinical and epidemiological records were
available for each patient.
The investigation was conducted in accordance with human
experimentation guidelines of the Romanian Ministry of Health and
with
those of the Centers for Disease Control and Prevention for
studies
conducted in rapid response to public health
emergencies.
WN MAC- and direct IgG ELISAs.
The antigens used in ELISAs
were prepared and optimized according to published methods (7,
29). Propagation of viruses was carried out in a biosafety level
3 laboratory. Briefly, antigens were prepared by infecting confluent
monolayers of monkey kidney cells (Vero cells; American Type Culture
Collection, catalog number CRL1587) with virus at approximately 0.1 PFU
per cell. Virus-infected cell cultures were harvested when they
exhibited three-plus cytopathic effect (CPE). Cell culture supernatants
were clarified by low-speed centrifugation, aliquoted, and frozen at
70°C. Infected cell pellets were resuspended with standard borate
saline, pH 9.6, containing 1% Triton X-100, sonicated, and clarified
by centrifugation. Cell lysates and culture supernatants were
inactivated by cobalt gamma irradiation (3 million rads) and safety
tested to ensure inactivation. This was accomplished by inoculating
Vero cells with the treated antigens and observing the cell monolayers
for CPE. To determine the optimal antigen dilution, we performed
checkerboard titrations against homologous reference sera. Cell lysates
were used to coat polyvinylchloride microtiter plates (Dynatech,
Vienna, Va.) for direct IgG ELISA, and the infected cell culture
supernatants were used as the antigen in the IgM capture ELISA
(MAC-ELISA). Mock antigens from uninfected cells were prepared in a
similar manner and used in control wells.
Viruses used to infect Vero cells included the EG101 strain of WN
virus, which was originally isolated in Egypt; the 17d strain
(Connaught) of yellow fever (YF) virus, derived by Theiler in
1937; the
New Guinea C strain of dengue 2 (DEN2) virus, a human
isolate from
1944; and the Hypr strain of Central European encephalitis
(tick-borne
encephalitis [TBE]) virus, originally isolated in
1953 from a patient
in
Czechoslovakia.
Serum samples were screened at a 1:100 dilution, and a subset of these
sera were serially diluted fourfold from 1:100 to 1:6,400
in the ELISA
plate. CSF was screened at 1:10. Homologous hyperimmune
mouse ascitic
fluid was used as the detector antibody in the MAC-ELISA.
This reagent
was prepared and optimized according to the methods
of Brandt et al.
(
2). The MAC-ELISA and the indirect assay
for IgG antibodies
were described previously (
7,
27,
29).
Optical densities
(OD) were determined with an automatic ELISA
plate reader (Diagnostics
Pasteur) at 405 nm. OD values for control
antigen wells were subtracted
from the values for corresponding
viral-antigen wells to obtain the
adjusted OD value of each test
sample. Cutoff values were established
by determining the mean
adjusted OD of four negative serum samples plus
3 standard deviations.
WN virus antigen was prepared by infecting
confluent Vero cell
monolayers with the Eg101 strain at approximately
0.1 PFU per
cell. Virus-infected cell cultures were harvested when they
exhibited
three-plus CPE. Cell culture supernatants were clarified by
low-speed
centrifugation, aliquoted, and frozen at

70°C. Infected
cell
pellets were resuspended with borate saline, pH 9.6, with 1%
Triton
X-100, sonicated for 10 min on ice, and clarified by low-speed
centrifugation. Cell lysates and culture supernatants were inactivated
by cobalt gamma irradiation (3 million rads) and safety tested
prior to
use. Cell lysate at an optimized dilution was used to
coat plates for
the IgG ELISA, and the infected cell culture supernatant
was used as
the MAC-ELISA antigen. Mock antigens from uninfected
cells were
prepared in a similar manner and used to coat control
wells.
A sample was considered positive if it had an adjusted OD value equal
to or greater than the cutoff value. The titer was equal
to the
reciprocal of the last dilution that was above or equal
to the OD
cutoff value. Positive control samples were sera from
vaccinated or
naturally infected persons that exhibited activity
in the appropriate
flavivirus ELISA. Negative control serum samples
were obtained from
flavivirus-naive
individuals.
Acute WN infection was confirmed if (i) anti-WN virus IgM with or
without IgG antibodies was present in the CSF or (ii) a
seroconversion
or a seroreversion of anti-WN virus IgG or IgM
antibodies was
demonstrated in sequential serum samples from the
same patient. The
diagnosis was considered presumptive if virus-specific
IgM was detected
only in serum or if virus-specific IgG was elevated
(a titer of

1:400) in one or more serum samples (
30). Patients
with
low levels of virus-specific IgG (a titer of <1:400) without
IgM were
classified as having had a past WN virus
infection.
Statistical analysis.
Statistical analysis was performed
with Microsoft Excel software. A two-tailed t test was used
to compare paired data. Logarithmic, polynomial, and linear regressions
and the Pearson r correlation were used to determine the
relationship between paired variables.
 |
RESULTS |
Specific IgM and IgG antibody response by clinical diagnosis.
Confirmed or presumptive WN virus infections were diagnosed in 236 (81%) of 290 patients hospitalized with various clinical disorders
(Table 1). The relatively low percentage of seroreactivity among
patients meeting the epidemiological case definition reflects the
absence of convalescent serum specimens in 24 cases. Patients meeting
the case definition but who lacked appropriate serologic confirmation
differed significantly from patients with confirmed cases of infection
in age, residence, and clinical diagnosis, suggesting that they
represented other summertime infections upon which the epidemic was
superimposed (24). WN virus infection was laboratory proven
in eight patients not meeting the case definition but who were
hospitalized with fever and headache. Remarkably, acute WN virus
infection was also diagnosed serologically in five patients with
respiratory tract infections and in seven patients hospitalized with
nonspecific febrile illnesses.
Kinetics of IgM and IgG antibody responses in serum and CSF.
WN virus antibodies were detectable as early as the first
hospitalization day in CSF and from the second day after the onset of
illness in serum samples (Fig. 1). During
the first week of illness, the cumulative percentage of patients who
became seropositive rose by approximately 10% each day. Patterns of
IgG and IgM reactivity in serum and CSF were examined in detail for
patients meeting the clinical case definition (Fig.
2). Among 60 patients who had acute-phase
serum samples (mean collection day, 4.1 ± 1.6; range, 2 to 7),
37% had virus-specific IgM only without specific IgG. The mean
collection day for these samples was 3.5 ± 0.9, significantly lower than the mean collection day for samples that had both IgM and
IgG, which was 4.9 ± 1.6 (P < 0.01). Thus, the
switch to an IgG antibody response occurred after 4 to 5 days of
illness. CSF samples collected from various days in the first week of
illness were available from 76 patients meeting the clinical case
definition (mean collection day, 3.7 ± 1.4; range, 2 to 7). The
switch to an IgG antibody response appeared to occur slightly earlier
in CSF than in serum. The mean collection day for CSF samples with specific IgM only was 3.7 ± 1.2, and for those having both IgM and IgG, the mean day was 3.8 ± 1.2 (P = 0.839)
(Fig. 1B). Among the 60 patients who fulfilled the clinical case
definition and who had acute-phase serum samples, 72% were
seropositive by the seventh day of illness (Fig. 2, column 1). An
additional 10% became seropositive by the end of the third week of
illness, and another 9% became seropositive only after 4 weeks of
illness, giving a total seroreactivity of 91%.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Cumulative percent positivity of anti-WN virus IgM and
IgG ELISA antibodies in sera (A) and CSF (B) of patients with confirmed
and presumptive recent WN virus infection by day after onset of
illness.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
Patterns of WN virus-specific IgM and IgG antibody
reactivity in CSF and serum by interval after onset of illness.
|
|
Cross-reactivity of acute-phase anti-WN antibodies with
flaviviruses in other antigenic groups.
Antibody responses of
infected subjects in areas where intense flavivirus activity occurs in
successive years can give rise to difficulties in serologic diagnosis.
As a rule, primary responders exhibit mainly monotypic antibody
responses, but with successive infections, the antibody response
broadens to include heterotypic reactivity to other flaviviruses in the
same or different antigenic groups. The occurrence of this outbreak in
a flavivirus-naive population allowed us to evaluate the specificities
of the ELISAs in primary WN virus infection. We selected at random 14 acute-phase samples, which were tested for IgM and IgG antibodies
against four flavivirus antigens (Table
2): WN virus, DEN virus, YF virus, and
TBE virus. The IgM immune responses were monotypic, while the IgG
antibodies exhibited a broader range of specificity in accordance with
the magnitude of the primary immune response.
Correlation between OD values and serum antibody titer.
In
Fig. 3, the mean OD values for a
twofold-dilution series of serum samples (beginning at 1:100) are
displayed for IgM and IgG. As expected from the multistep protocol
used, OD values in the MAC-ELISA show great variability and practically
no linearity. The best-fit regression for IgM OD values was a
polynomial relationship (R = 0.93) in which low OD
values corresponded to low antibody concentration and high OD values
corresponded to high antibody concentration. Reactivity in the
MAC-ELISA usually persisted in dilutions of >1:10,000 and occasionally
>1:50,000 (data not shown), reflecting the presence of very high
levels of WN virus-specific IgM antibodies in the samples and/or a high
sensitivity of the assay system. With respect to IgG OD values for the
same dilutions, Fig. 3B shows a much lower variability among replicates
and a better polynomial correlation between OD values and dilutions (R = 0.98). The linearity of the relationship in the
region with serum diluted 1:100 to 1:800 (Fig. 3B) allowed an accurate
estimation of IgG serum concentration from the sample OD value. After
serial dilution, reactivity was extinguished more rapidly for IgG than for IgM, with no reactivity beyond a dilution of 1:6,400.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Correlation between OD values and IgM (A) and IgG (B)
antibody concentrations in serum. Sera with high IgM and IgG WN
virus-specific antibody titers were tested in twofold dilutions; the
bars represent the mean OD value for each given serum dilution, and
error bars were set at ±1 standard deviation of the mean. The trend
line equation and R2 values are shown.
|
|
Correlation between OD values and illness day.
OD values for
serum IgM showed a general decline through the first 3 months after the
onset of illness (Fig. 4A). The mean OD
value of samples in the first 20 days of illness, 1.230 ± 0.733, was significantly higher (P < 0.0001) than the mean OD
of later samples, 0.618 ± 0.401. Generally, high OD values in the
IgM assay corresponded to a recent infection while low OD values
corresponded to a more distantly acquired infection, 1 to 3 months
before serum collection (slope,
16.7; R =
0.43; P < 0.01). More precisely, an adjusted IgM OD value of more than
1.000 had a probability of 0.62 of indicating a recent infection
(within 1 month), and an IgM OD value of less than 1.000 had a
probability of 0.95 of indicating an infection older than 1 month. More
than 50% of cases had IgM persisting beyond 2 months after the onset
of illness. OD values for IgG were more scattered (Fig. 4B), although a
tendency toward an incremental increase is evident (slope, 13.5;
R = 0.432; P < 0.01). The mean IgG OD value
during the first 20 days of illness (1.519 ± 0.880) was
significantly lower than the mean OD value found in later samples
(2.249 ± 0.732; P < 0.01).
 |
DISCUSSION |
The epidemic in Romania was the first significant WN fever
outbreak reported in Europe. The uniformly low seroprevalence rates in
all age groups recorded in a postepidemic serosurvey suggests that the
virus was newly introduced into an immunologically naive population
(31). This may explain the unprecedented number of neurological cases and deaths, especially among elderly persons. In the
1996 epidemic, 835 clinically suspected cases were reported, but in 326 that met the case definition, appropriate clinical specimens to confirm
a laboratory diagnosis were unavailable. This gap underscores a
critical need for clinical laboratory procedures that can be applied to
specimens obtained early in the illness.
The accepted diagnostic categories for defining a case of arboviral
encephalitis specify a compatible clinical syndrome and (i)
virus-specific IgM in CSF or a fourfold rise in serum antibody titer by
ELISA, indirect immunofluorescent antibody assay (IFA), complement
fixation (CF), hemagglutination inhibition (HI), or neutralization
(confirmed case); (ii) elevated antibody titer in a single serum sample
(e.g., >320 by HI, >256 by IFA, >128 by CF, >160 by 90% plaque
reduction neutralization, or virus-specific IgM in the serum) (probable
case); or (iii) occurrence during a period when arbovirus transmission
is likely (suspected case) (30).
During the Romanian epidemic, 84% of patients meeting the clinical
case criteria were laboratory confirmed or were considered probable,
based on the presence of anti-WN virus IgM antibodies in CSF or serum
samples collected in the first week of illness. In serum samples
collected in the same interval from patients hospitalized with other
clinical conditions, only 61% had virus-specific IgM antibodies. In
51% of patients with samples available during the first week after
hospital admission, IgM antibodies were detected in the CSF only, while
IgM was detected in only 37% of early serum samples. In some cases,
when both serum and CSF samples taken the same day were available, the
onset of IgM antibody synthesis was reported first in the CSF. This
observation underscores the importance of collecting CSF specimens for
serologic testing at the earliest stages of illness. The MAC-ELISA has
demonstrated a high degree of sensitivity and specificity in the
serologic diagnosis of other neurotropic flaviviral infections when
both serum and CSF samples were tested, paralleling the results
reported here (4, 14).
The appearance of IgM in the CSF before it appears in the serum
indicates that antibody production began locally in the CNS and that
its presence did not merely reflect transudation from the systemic
circulation (4, 5, 14). IgM antibodies were still present 2 months after the onset of illness in more than 50% of convalescent
serum samples. The overall decline in antibody titers with time does
not exclude the possibility that high titers in some samples could
reflect viral persistence. Chronic neurological infections have been
produced in monkeys experimentally infected with WN virus, and
naturally acquired Japanese encephalitis infections have been followed
by delays in virus clearance, by clinical relapses, and by the
persistence of intrathecal viral antigen for several weeks and
intrathecal IgM antibodies for several months (22, 25, 28).
The persistence of serum IgM antibodies for up to 3 decades in
recipients of live attenuated YF vaccine has been reported, presumably
reflecting viral persistence (23). Efforts are being made to
follow recovered WN encephalitis patients in this outbreak to study the
disappearance or continued persistence of IgM antibodies.
Serum IgG antibodies were present in 90% of convalescent sera
collected between 2 and 3 months after the onset of illness. The
absence of IgG antibodies in the seroprevalence study conducted during
the epidemic investigation is evidence that WN virus was newly
introduced to Bucharest in 1996. The only other flaviviral infection
recognized in Romania is TBE virus infection, which is transmitted in
northern Romania, where it is the etiology of 20 to 30 encephalitis
cases annually (8, 9). In primary infections, antibodies to
TBE and WN viruses are likely to show cross-reactivity by either HI or
ELISA only in samples with high antibody titers. Our evaluation showed
that anti-WN virus IgM antibodies detected by MAC-ELISA were highly
specific but that IgG ELISA antibodies exhibited some cross-reactivity.
In the wake of the 1996 epidemic, surveillance of acute encephalitis
cases was established in districts affected by the outbreak, including
Bucharest, and 13 sporadic cases were detected in 1997 and 1998 (6). The gradual diminution of viral transmission in the
years after an outbreak, also observed after St. Louis encephalitis
epidemics in the United States, may reflect the continued depletion of
susceptible amplifying and end hosts, extension of intermediate-term
meteorological patterns favoring viral transmission, or the changing
sensitivity of case detection. Previous field studies in the Danube
Delta in southeastern Romania had suggested that the virus was
transmitted in a local sylvatic cycle (8, 9). Details of the
sylvatic transmission cycle there or elsewhere in Europe have not been
well defined, and the novel circumstances that led to epidemic urban
transmission in 1996 are even more obscure. By analogy from the
epidemiology of St. Louis encephalitis in the western United States, WN
virus may be transmitted perennially in rural areas of southern Europe,
producing an endemic pattern of infection in the local population.
Under unusual circumstances of amplified transmission, the virus may
spill over to urban locations, where susceptible human populations and
the proximity and abundance of vector mosquitoes and of intermediate
avian amplifying hosts provide conditions for epidemic transmission
(18, 31).
Little is known of the incidence or geographic distribution of WN
encephalitis in Europe because the disease is not routinely considered
in the differential diagnosis of neurological infection and because
laboratory diagnosis is not readily available. The 1996 epidemic in
Romania, associated suspect cases in Bulgaria, an equine epizootic in
Italy, and a recent study from western Georgia in which WN virus
antibodies were reported in 31% of patients with acute CNS infection
suggest that WN virus infections may have public health significance in
a larger area of eastern and southern Europe than has been appreciated
previously (6, 13; Tsereteli et al., Proc. 8th Int.
Congr. Infect. Dis.). In addition, the recent emergence of a WN
virus-like outbreak in the United States signals the potential for an
even wider, global distribution (1, 3). The dissemination of
sensitive and specific laboratory test systems, such as MAC-ELISA, to
confirm the diagnosis and of IgG ELISAs to aid in serosurveys will
greatly facilitate comprehension of the public health burden of this
previously neglected infection.
 |
ACKNOWLEDGMENTS |
We are grateful to the staff epidemiologists of the Bucharest
Preventive Medicine Department for tracing cases and to the staff
clinicians of the Dr. Victor Babes and N. Gh. Lupu Hospitals of
infectious diseases in Bucharest for providing clinical samples and data.
The investigation was supported under an interagency agreement between
the United States Agency for International Development and the
Department of Health and Human Services.
 |
FOOTNOTES |
*
Corresponding author. Present address: Wyeth Lederle
Vaccines, 401 N. Middletown Rd., Pearl River, NY 10965. Phone: (914) 732-4053. E-mail: tsait{at}war.wveth.com.
 |
REFERENCES |
| 1.
|
Anonymous.
1999.
Outbreak of West Nile-like viral encephalitis-New York, 1999.
Morb. Mortal. Wkly. Rep.
48:845-849[Medline].
|
| 2.
|
Brandt, W.,
E. L. Buescher, and F. M. Hetrick.
1967.
Production and characterization of arbovirus antibody in mouse ascitic fluid.
Am. J. Trop. Med. Hyg.
16:339-347.
|
| 3.
|
Briese, T.,
X. Y. Jia,
C. Huang,
L. J. Grady, and W. I. Lipkin.
1999.
Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis.
Lancet
354:1261-1262[CrossRef][Medline].
|
| 4.
|
Burke, D. S.,
A. Nisalak,
M. A. Ussery,
T. Laorakongse, and S. Chantavibul.
1985.
Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid.
J. Infect. Dis.
151:1093-1099[Medline].
|
| 5.
|
Cernescu, C.,
S. M. Ruta,
G. Tardei,
C. Grancea,
L. Moldovan,
E. Spulbar, and T. F. Tsai.
1997.
A high number of severe neurologic clinical forms during an epidemic of West Nile virus infection.
Rom. J. Virol.
48:13-25[Medline].
|
| 6.
|
Cernescu, C.,
N. I. Nedelcu,
G. Tardei,
S. Ruta, and T. F. Tsai.
2000.
Continued transmission of West Nile virus to humans in southeastern Romania, 1997-1998.
J. Infect. Dis.
181:710-712[CrossRef][Medline].
|
| 7.
|
Chu, Y. K.,
C. Rossi,
J. LeDu,
H. Lee,
C. Schmaljohn, and J. Dalrymple.
1994.
Serological relationships among viruses in the Hantavirus genus, family Bunyaviridae.
Virology
198:196-204[CrossRef][Medline].
|
| 8.
|
Draganescu, N.,
E. Garjabu,
R. Iftimovici, and E. Klebleev.
1991.
Études sérologiques sur la présence de quelques arbovirus dans la région de sylvo-steppe de Tulcea.
Rev. Roum. Virol.
42:47-51.
|
| 9.
|
Draganescu, N.,
E. Girjabu, and R. Iftimovici.
1993.
Investigations sérologiques chez l'homme et chez differentes espèces d'animaux domestiques de la région de sylvo-steppe de Roumanie, pour le dépistage de quelques Togaviridae et Bunyaviridae.
Rev. Roum. Virol.
44:207-210.
|
| 10.
|
George, N. J.,
J. L. Lesbordes,
M. C. Georges-Courbet,
D.M.Y. Meunier, and J. P. Gonzalez.
1987.
Fatal hepatitis from West Nile virus.
Ann. Inst. Pasteur
138:237-244.
|
| 11.
|
George, S.,
S. R. Prasad,
J. A. Rao,
P. N. Yergolkar, and C. V. Sreenivasaiah Setty.
1987.
Isolation of Japanese encephalitis and West Nile viruses from fatal cases of encephalitis in Kolar district of Karnataka.
Indian J. Med. Res.
86:131-134[Medline].
|
| 12.
|
Hayes, C. G.
1989.
West Nile fever, p. 59-88.
In
T. F. Monath (ed.), The arboviruses: epidemiology and ecology, vol. V. CRC Press, Boca Raton, Fla.
|
| 13.
|
Hubalek, Z., and J. Haouzka.
1999.
West Nile fever, a reemerging mosquito-borne viral disease in Europe.
Emerg. Infect. Dis.
5:643-650[Medline].
|
| 14.
|
Innis, B. L.,
S. Nisalak,
S. Nimmannitya,
S. Kusalerdchariya,
V. Chongswasdi,
S. Suntayakorn,
P. Puttisri, and C. H. Hoke.
1991.
An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate.
Am. J. Trop. Med. Hyg.
40:418-427.
|
| 15.
|
Marberg, K.,
N. Goldblum,
V. Stork,
W. Jasinska-Klingberg, and M. Klingberg.
1956.
The natural history of West Nile fever. I. Clinical observations during an epidemic in Israel.
Am. J. Hyg.
69:259-269.
|
| 16.
|
McIntosh, B. M.,
P. G. Jupp,
I. Dos Santos, and G. M. Meeneham.
1976.
Epidemics of West Nile and Sindbis viruses in South Africa with Culex (Culex) univittatus Theobald as a vector.
S. Afr. J. Sci.
72:295-300.
|
| 17.
|
Mitchell, C. J.
1995.
Geographic spread of Aedes albopictus and potential for involvement in arbovirus cycles in the Mediterranean Basin.
J. Vector Ecol.
20:44-58.
|
| 18.
|
Monath, T. P., and T. F. Tsai.
1997.
Flaviviruses, p. 1133-1186.
In
D. D. Richman, R. J. Whitley, and F. G. Hayden (ed.), Clinical virology. Churchill-Livingstone, New York, N.Y.
|
| 19.
|
Panthier, R.,
C. Hannoun,
D. Beytout, and J. Mouchet.
1968.
Epidemiologie du virus West Nile. Etude d'un foyer en Camargue. 3. Les maladies humaines.
Ann. Inst. Pasteur
115:435-445[Medline].
|
| 20.
|
Peiris, J. S. M., and F. P. Amerasinghe.
1994.
West Nile fever, p. 139-148.
In
G. W. Beran (ed.), Handbook of zoonoses, section B. Viral, 2nd ed. CRC Press, Boca Raton, Fla.
|
| 21.
|
Perelman, A., and J. Stern.
1974.
Acute pancreatitis in West Nile fever.
Am. J. Trop. Med. Hyg.
23:1150-1152.
|
| 22.
|
Pogodina, V. V.,
M. P. Frolova,
G. V. Malenko,
G. I. Fokina,
G. V. Koreshkova,
L. L. Kiseleva,
N. G. Bochkova, and N. M. Ralph.
1983.
Study on West Nile virus persistence in monkeys.
Arch. Virol.
75:71-86[CrossRef][Medline].
|
| 23.
|
Poland, J. D.,
C. H. Calisher,
T. P. Monath,
W. G. Downs, and K. Murphy.
1981.
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
Bull. W. H. O.
59:895-900[Medline].
|
| 24.
|
Porter, K. R.,
P. L. Summers,
D. Dubois,
B. Puri,
W. Nelson,
E. Henchal,
J. J. Oprandy, and C. G. Hayes.
1993.
Detection of West Nile virus by the polymerase chain reaction and analysis of nucleotide sequence variation.
Am. J. Trop. Med. Hyg.
48:440-446.
|
| 25.
|
Ravi, V.,
A. Desai,
P.K. Shenoy,
P. Satishchandra,
A. Chandramuki, and M. Gourie-Devi.
1993.
Persistence of Japanese encephalitis virus in the human nervous system.
J. Med. Virol.
40:326-329[Medline].
|
| 26.
|
Savage, H. M.,
C. Ceianu,
G. Nicolescu,
N. Karabatsos,
R. Lanciotti,
A. Vladimirescu,
L. Laiv,
A. Ungureanu,
C. Romanca, and T. F. Tsai.
1999.
Entomological and avian investigations of an epidemic of West Nile fever in Romania, 1996, with serological and molecular characterization of a virus isolate from mosquitoes.
Am. J. Trop. Med. Hyg.
61:600-611[Abstract].
|
| 27.
|
Schmaljohn, C.,
L. Vanderzanden,
M. Bray,
D. Custer,
B. Meyer,
D. Li,
C. Rossi,
D. Fuller,
J. Fuller,
J. Haynes, and J. Huggins.
1997.
Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.
J. Virol.
71:9563-9569[Abstract].
|
| 28.
|
Sharma, S.,
A. Mathur,
R. Prakash,
R. Kulshreshtha,
R. Kumar, and U. C. Chaturvedi.
1991.
Japanese encephalitis virus latency in peripheral blood lymphocytes and recurrence of infection in children.
Clin. Exp. Immunol.
85:85-89[Medline].
|
| 29.
|
Sharp, T. R.,
M. R. Wallace,
C. G. Hayes,
J. L. Sanchez,
R. F. Defraites,
R. R. Arthur,
S. A. Thornton,
R. A. Batchelor,
P. J. Rosmajzl,
R. K. Hanson,
S. J. Wu,
C. Iriye, and J. P. Burans.
1996.
Dengue fever in US troops during Operation Restore Hope, Somalia, 1992-1993.
Am. J. Trop. Med. Hyg.
53:89-94.
|
| 30.
|
Tsai, T. F.
1999.
Arboviruses, p. 1107-1124.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
|
| 31.
|
Tsai, T. F.,
F. Popovici,
C. Cernescu,
G. C. Campbell,
N. I. Nedelcu, and the Investigative Team.
1998.
West Nile encephalitis epidemic in southeastern Romania.
Lancet
352:767-771[CrossRef][Medline].
|
| 32.
|
Varsano, M.,
M. B. Basat, and L. Rannon.
1982.
West Nile virus infection in recent years in Israel.
Isr. J. Med. Sci.
19:11.
|
Journal of Clinical Microbiology, June 2000, p. 2232-2239, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tyler, K. L.
(2009). Emerging Viral Infections of the Central Nervous System: Part 1. Arch Neurol
66: 939-948
[Abstract]
[Full Text]
-
Shaikh, N. A., Ge, J., Zhao, Y.-X., Walker, P., Drebot, M.
(2007). Development of a novel, rapid, and sensitive immunochromatographic strip assay specific for West Nile Virus (WNV) IgM and testing of its diagnostic accuracy in patients suspected of WNV infection.. Clin. Chem.
53: 2031-2034
[Full Text]
-
Roberson, J. A., Crill, W. D., Chang, G.-J. J.
(2007). Differentiation of West Nile and St. Louis Encephalitis Virus Infections by Use of Noninfectious Virus-Like Particles with Reduced Cross-Reactivity. J. Clin. Microbiol.
45: 3167-3174
[Abstract]
[Full Text]
-
Tyler, K. L., Aksamit, A. J. Jr, Keegan, B. M., Parisi, J. E.
(2007). An 85-year-old man with chronic lymphocytic leukemia and altered mental status. Neurology
68: 460-467
[Full Text]
-
Cordoba, L., Escribano-Romero, E., Garmendia, A., Saiz, J.-C.
(2007). Pregnancy increases the risk of mortality in West Nile virus-infected mice. J. Gen. Virol.
88: 476-480
[Abstract]
[Full Text]
-
Macdonald, J., Tonry, J., Hall, R. A., Williams, B., Palacios, G., Ashok, M. S., Jabado, O., Clark, D., Tesh, R. B., Briese, T., Lipkin, W. I.
(2005). NS1 Protein Secretion during the Acute Phase of West Nile Virus Infection. J. Virol.
79: 13924-13933
[Abstract]
[Full Text]
-
Prince, H. E., Tobler, L. H., Lape-Nixon, M., Foster, G. A., Stramer, S. L., Busch, M. P.
(2005). Development and Persistence of West Nile Virus-Specific Immunoglobulin M (IgM), IgA, and IgG in Viremic Blood Donors. J. Clin. Microbiol.
43: 4316-4320
[Abstract]
[Full Text]
-
Tilley, P. A. G., Walle, R., Chow, A., Jayaraman, G. C., Fonseca, K., Drebot, M. A., Preiksaitis, J., Fox, J.
(2005). Clinical Utility of Commercial Enzyme Immunoassays during the Inaugural Season of West Nile Virus Activity, Alberta, Canada. J. Clin. Microbiol.
43: 4691-4695
[Abstract]
[Full Text]
-
Johnson, A. J., Noga, A. J., Kosoy, O., Lanciotti, R. S., Johnson, A. A., Biggerstaff, B. J.
(2005). Duplex Microsphere-Based Immunoassay for Detection of Anti-West Nile Virus and Anti-St. Louis Encephalitis Virus Immunoglobulin M Antibodies. CVI
12: 566-574
[Abstract]
[Full Text]
-
Hogrefe, W. R., Moore, R., Lape-Nixon, M., Wagner, M., Prince, H. E.
(2004). Performance of Immunoglobulin G (IgG) and IgM Enzyme-Linked Immunosorbent Assays Using a West Nile Virus Recombinant Antigen (preM/E) for Detection of West Nile Virus- and Other Flavivirus-Specific Antibodies. J. Clin. Microbiol.
42: 4641-4648
[Abstract]
[Full Text]
-
Shu, P.-Y., Chen, L.-K., Chang, S.-F., Su, C.-L., Chien, L.-J., Chin, C., Lin, T.-H., Huang, J.-H.
(2004). Dengue Virus Serotyping Based on Envelope and Membrane and Nonstructural Protein NS1 Serotype-Specific Capture Immunoglobulin M Enzyme-Linked Immunosorbent Assays. J. Clin. Microbiol.
42: 2489-2494
[Abstract]
[Full Text]
-
Gea-Banacloche, J., Johnson, R. T., Bagic, A., Butman, J. A., Murray, P. R., Agrawal, A. G.
(2004). West Nile Virus: Pathogenesis and Therapeutic Options. ANN INTERN MED
140: 545-553
[Abstract]
[Full Text]
-
Malan, A. K., Martins, T. B., Hill, H. R., Litwin, C. M.
(2004). Evaluations of Commercial West Nile Virus Immunoglobulin G (IgG) and IgM Enzyme Immunoassays Show the Value of Continuous Validation. J. Clin. Microbiol.
42: 727-733
[Abstract]
[Full Text]
-
Prince, H. E., Lape'-Nixon, M., Moore, R. J., Hogrefe, W. R.
(2004). Utility of the Focus Technologies West Nile Virus Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Testing Cerebrospinal Fluid. J. Clin. Microbiol.
42: 12-15
[Abstract]
[Full Text]
-
Wong, S. J., Demarest, V. L., Boyle, R. H., Wang, T., Ledizet, M., Kar, K., Kramer, L. D., Fikrig, E., Koski, R. A.
(2004). Detection of Human Anti-Flavivirus Antibodies with a West Nile Virus Recombinant Antigen Microsphere Immunoassay. J. Clin. Microbiol.
42: 65-72
[Abstract]
[Full Text]
-
Engle, M. J., Diamond, M. S.
(2003). Antibody Prophylaxis and Therapy against West Nile Virus Infection in Wild-Type and Immunodeficient Mice. J. Virol.
77: 12941-12949
[Abstract]
[Full Text]
-
Prince, H. E., Hogrefe, W. R.
(2003). Detection of West Nile Virus (WNV)-Specific Immunoglobulin M in a Reference Laboratory Setting during the 2002 WNV Season in the United States. CVI
10: 764-768
[Abstract]
[Full Text]
-
Iwamoto, M., Jernigan, D. B., Guasch, A., Trepka, M. J., Blackmore, C. G., Hellinger, W. C., Pham, S. M., Zaki, S., Lanciotti, R. S., Lance-Parker, S. E., DiazGranados, C. A., Winquist, A. G., Perlino, C. A., Wiersma, S., Hillyer, K. L., Goodman, J. L., Marfin, A. A., Chamberland, M. E., Petersen, L. R., the West Nile Virus in Transplant Recipients Inves,
(2003). Transmission of West Nile Virus from an Organ Donor to Four Transplant Recipients. NEJM
348: 2196-2203
[Abstract]
[Full Text]
-
Pepperell, C., Rau, N., Krajden, S., Kern, R., Humar, A., Mederski, B., Simor, A., Low, D. E., McGeer, A., Mazzulli, T., Burton, J., Jaigobin, C., Fearon, M., Artsob, H., Drebot, M. A., Halliday, W., Brunton, J.
(2003). West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ
168: 1399-1405
[Abstract]
[Full Text]
-
Blitvich, B. J., Marlenee, N. L., Hall, R. A., Calisher, C. H., Bowen, R. A., Roehrig, J. T., Komar, N., Langevin, S. A., Beaty, B. J.
(2003). Epitope-Blocking Enzyme-Linked Immunosorbent Assays for the Detection of Serum Antibodies to West Nile Virus in Multiple Avian Species. J. Clin. Microbiol.
41: 1041-1047
[Abstract]
[Full Text]
-
Diamond, M. S., Shrestha, B., Marri, A., Mahan, D., Engle, M.
(2003). B Cells and Antibody Play Critical Roles in the Immediate Defense of Disseminated Infection by West Nile Encephalitis Virus. J. Virol.
77: 2578-2586
[Abstract]
[Full Text]
-
Prince, H. E., Hogrefe, W. R.
(2003). Performance Characteristics of an In-House Assay System Used To Detect West Nile Virus (WNV)-Specific Immunoglobulin M during the 2001 WNV Season in the United States. CVI
10: 177-179
[Abstract]
[Full Text]
-
Martin, D. A., Biggerstaff, B. J., Allen, B., Johnson, A. J., Lanciotti, R. S., Roehrig, J. T.
(2002). Use of Immunoglobulin M Cross-Reactions in Differential Diagnosis of Human Flaviviral Encephalitis Infections in the United States. CVI
9: 544-549
[Abstract]
[Full Text]
-
Craven, R. B., Roehrig, J. T.
(2001). West Nile Virus. JAMA
286: 651-653
[Full Text]
-
Davis, B. S., Chang, G.-J. J., Cropp, B., Roehrig, J. T., Martin, D. A., Mitchell, C. J., Bowen, R., Bunning, M. L.
(2001). West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays. J. Virol.
75: 4040-4047
[Abstract]
[Full Text]